- Conditions
- Breast Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Glioblastoma, Renal Cell Cancer
- Interventions
- Not listed
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 276 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 50
- States / cities
- Many Locations, Alabama • Many Locations, Alaska • Many Locations, Arizona + 47 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 481–504
of 3,680
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lung Cancer
- Interventions
- canfosfamide hydrochloride
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Lung Neoplasms
- Interventions
- Radiation with Concurrent Chemotherapy
- Radiation
- Lead sponsor
- Proton Collaborative Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2013
- U.S. locations
- 6
- States / cities
- Jacksonville, Florida • Warrenville, Illinois • Baltimore, Maryland + 3 more
- Conditions
- Locally Advanced Solid Tumor, Metastatic Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Mesothelioma, Melanoma, Head and Neck Cancer
- Interventions
- CTX-471, Pembrolizumab (KEYTRUDA®)
- Drug
- Lead sponsor
- Compass Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 10
- States / cities
- Ocala, Florida • Port Saint Lucie, Florida • Boston, Massachusetts + 6 more
- Conditions
- Non-Small-Cell Lung Carcinoma, Prostate Cancer, Bladder Cancer, Urothelial Carcinoma
- Interventions
- vorinostat (suberoylanilide hydroxamic acid), docetaxel
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Cetuximab, Carboplatin, Paclitaxel
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 20
- States / cities
- Los Angeles, California • Santa Monica, California • Newark, Delaware + 17 more
- Conditions
- Activating ALK Gene Mutation Negative, Activating EGFR Gene Mutation Negative, Activating ROS1 Gene Mutation Negative, Health Care Provider, Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Counseling, Questionnaire Administration, Medical Chart Review
- Other
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Non-small Cell Lung Cancer, Vomiting, Nausea, Emesis
- Interventions
- FOSAPREPITANT (Emend), Placebo
- Drug
- Lead sponsor
- Ajeet Gajra
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Syracuse, New York
- Conditions
- Lung Cancer
- Interventions
- carboplatin, cisplatin, gemcitabine hydrochloride, paclitaxel
- Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 13
- States / cities
- Atlanta, Georgia • Des Moines, Iowa • Papillion, Nebraska + 8 more
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer, Colorectal Cancer
- Interventions
- [68Ga]Ga-NNS309, [177Lu]Lu-NNS309
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 6 more
- Conditions
- Anaplastic Astrocytoma, IDH-Wildtype, Glioblastoma, IDH-Wildtype, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Central Nervous System, Stage IV Lung Cancer AJCC v8
- Interventions
- Biospecimen Collection - blood samples, Biospecimen Collection - CSF samples, Computed Tomography, EGFR/EGFRvIII Inhibitor WSD0922-FU, Magnetic Resonance Imaging, Therapeutic Conventional Surgery
- Procedure · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2031
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Lung Cancer
- Interventions
- bevacizumab, docetaxel
- Biological · Drug
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 75 Years to 120 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 3
- States / cities
- Detroit, Michigan • Las Vegas, Nevada • Cleveland, Ohio
- Conditions
- Advanced Solid Tumors Cancer
- Interventions
- ABBV-321
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 14
- States / cities
- Springdale, Arkansas • Los Angeles, California • Sacramento, California + 10 more
- Conditions
- Depression, Lung Cancer
- Interventions
- counseling intervention, screening questionnaire administration, study of socioeconomic and demographic variables, psychosocial assessment and care
- Other · Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 2
- States / cities
- Lexington, Kentucky • New York, New York
- Conditions
- Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin, Non-small Cell Lung Cancer (NSCLC), Prostate Cancer, Ovarian Cancer, Renal Carcinoma (Clear and Non-clear Cell), Head and Neck Squamous Cell Carcinoma (HNSCC), Hepatic Cancer, Gastric Cancer, Triple-negative Breast Cancer (TNBC)
- Interventions
- EXS74539
- Drug
- Lead sponsor
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Fort Worth, Texas • West Valley City, Utah
- Conditions
- Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Esophageal Squamous Cell Carcinoma (ESCC)
- Interventions
- Lomvastomig
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 2
- States / cities
- New York, New York • Houston, Texas
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Salivary Gland Squamous Cell Carcinoma, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer, Untreated Metastatic Squamous Neck Cancer With Occult Primary
- Interventions
- Cytology specimen, Laboratory biomarker analysis
- Other
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Solid Tumor, Adult
- Interventions
- DF1001, Nivolumab, Nab paclitaxel, Sacituzumab Govitecan-hziy
- Drug
- Lead sponsor
- Dragonfly Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 16
- States / cities
- Irvine, California • Los Angeles, California • San Diego, California + 13 more
- Conditions
- Carcinoma, Non-small Cell Lung Cancer
- Interventions
- nivolumab, ipilimumab, cabozantinib, docetaxel, ramucirumab, lucitanib
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor, Cancer, Cancer of Pancreas, Cancer of Colon
- Interventions
- HBI-2376
- Drug
- Lead sponsor
- HUYABIO International, LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 11
- States / cities
- Duarte, California • Encinitas, California • Fullerton, California + 7 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Lucanix® (belagenpumatucel-L)
- Biological
- Lead sponsor
- NovaRx Corporation
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Lung Cancer, Nonsmall Cell
- Interventions
- Crizotinib
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
- Interventions
- Biospecimen Collection, Computed Tomography, Echocardiography Test, Nivolumab, Observation Activity, Positron Emission Tomography
- Procedure · Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 903 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 884
- States / cities
- Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 638 more
- Conditions
- Advanced Solid Tumor
- Interventions
- M0324, Pembrolizumab, mFOLFIRINOX
- Biological · Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 3
- States / cities
- New Haven, Connecticut • New York, New York • San Antonio, Texas